Biocryst Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.
Did you know?
BCRX's revenue grew at a 61.8% CAGR over the last 6 years.
Current Price
$9.19
+0.33%Profile
Valuation (TTM)
Market Cap$1.93B
P/E7.33
EV—
P/B—
Shares Out210.54M
P/Sales2.21
Revenue$874.84M
EV/EBITDA6.15
Biocryst Pharmaceuticals Inc (BCRX) Stock Analysis
Market Cap$1.93B
Current Price$9.19
P/E Ratio7.33
Forward P/E—
PEG Ratio-0.01
EPS$1.21
Book Value$-0.57
P/B Ratio—
BCRX Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Debt: 387M
Revenue
49M
FY19
18M
FY20
157M
FY21
271M
FY22
331M
FY23
451M
FY24
875M
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
264M
FY25
BCRX 52-Week Range
$6.24
$11.19
50-Day MA: $9.00200-Day MA: $7.88
Did you know?
BCRX's revenue grew at a 61.8% CAGR over the last 6 years.
Biocryst Pharmaceuticals Inc (BCRX) Financial Summary
Biocryst Pharmaceuticals Inc (BCRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $9.19 with a market capitalization of $1.93B.
Key valuation metrics include a P/E ratio of 7.33, and EPS of $1.21. The company reports a profit margin of 30.2%.
BCRX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $1.93B |
| P/E Ratio | 7.33 |
| EPS | $1.21 |
| P/S Ratio | 2.21 |
| EV/EBITDA | 6.15 |
| Profit Margin | 30.2% |
BCRX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $48.84M | $-108.90M |
| FY20 | $17.81M | $-182.81M |
| FY21 | $157.17M | $-184.06M |
| FY22 | $270.83M | $-247.12M |
| FY23 | $331.41M | $-226.54M |
| FY24 | $450.71M | $-88.88M |
| FY25 | $874.84M | $263.86M |
BCRX Quality Indicators
Biocryst Pharmaceuticals Inc maintains a profit margin of 30.2% and an operating margin of 39.0%. The current ratio is 2.06.
About Biocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.
BCRX Free Cash Flow
Biocryst Pharmaceuticals Inc generated $344.90M in trailing twelve-month free cash flow, representing an FCF yield of 17.83%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
BCRX Shares Outstanding
Biocryst Pharmaceuticals Inc has 0.21 billion shares outstanding at a share price of $9.19, giving it a market capitalization of $1.93B.